Inactive Instrument

Medigard Limited

Equities

MGZ

AU000000MGZ2

Medigard Limited Reports Earnings Results for the Half Year Ended December 31, 2019

February 28, 2020 at 04:21 am IST

Medigard Limited announced earnings results for the half year ended December 31, 2019. For the half year, the company announced sales was AUD 0 compared to AUD 12,365 a year ago. Net income was AUD 494,578 compared to net loss of AUD 705,870 a year ago. Basic earnings per share was AUD 0.00348 compared to basic loss per share of AUD 0.00522 a year ago.

Latest news about Medigard Limited

Medigard Limited Reports Earnings Results for the Full Year Ended June 30, 2020	31/20/31	CI
MEDIGARD LIMITED Announces Project Licence Payments and Possible Termination	30/20/30	CI
Medigard Limited Reports Earnings Results for the Half Year Ended December 31, 2019	28/20/28	CI
Medigard Limited Reports Earnings Results for the Full Year Ended June 30, 2019	29/19/29	CI
Medigard Limited Reports Earnings Results for the Half Year Ended December 31, 2018	27/19/27	CI
Medigard Limited Announces Worldwide License Agreement with Kunovus Pty Ltd	08/18/08	CI
Medigard Limited Announces Earnings Results for the Year Ended on June 30, 2018	30/18/30	CI
Medigard Limited announced that it has received AUD 0.3 million in funding	31/18/31	CI
Medigard Limited Reports Audited Earnings Results for the First Half Year Ended December 31, 2017	28/18/28	CI
Medigard Ltd Announces the Formation of Scientific and Medical Advisory Panel	19/17/19	CI
Medigard Limited Appoints Ian Dixon as an Executive Director	21/17/21	CI
Medigard Limited announced that it expects to receive AUD 0.15 million in funding	31/17/31	CI
Medigard Limited Announces Audited Earnings Results for the Year Ended on June 30, 2017	30/17/30	CI
Medigard Ltd Announces Board Changes	20/17/20	CI
Medigard Limited Announces executive changes	14/17/14	CI
Medigard Limited Announces Earnings Results for the Year Ended on June 30, 2017	31/17/31	CI
Medigard Limited Reports Earnings Results for the Half Year Ended December 31, 2016	28/17/28	CI
Medigard Limited announced that it has received AUD 0.26 million in funding from Sol-Millennium Medical Products Co., Ltd.	13/16/13	CI
Medigard Limited announced that it expects to receive AUD 0.26 million in funding from Sol-Millennium Medical Products Co., Ltd.	25/16/25	CI
Medigard Limited Reports Earnings Results for the Full Year Ended June 30, 2016	25/16/25	CI
Medigard Limited Auditor Raises 'Going Concern' Doubt	23/15/23	CI
Medigard Limited Reports Earnings Results for the Full Year Ended June 30, 2015	31/15/31	CI
Medigard Limited announced that it has received AUD 0.3 million in funding from Sol-Millennium Medical Products Co., Ltd..	09/15/09	CI
Medigard Limited Auditor Raises 'Going Concern' Doubt	29/14/29	CI
Medigard Limited announced that it expects to receive AUD 0.30 million in funding from Shanghai Sol-millennium Medical Products Co., Ltd.	31/14/31	CI

Chart Medigard Limited

Duration

Period

More charts

Company Profile

Medigard Limited is engaged in the development of medical instruments in Australia. The principal activities of the Company are liaising with Shanghai Sol-Millennium Medical Products Co., Ltd for the improvement of the Blood Collection Device; bundling of the Blood Collection Device with its Flash Back Needle, and the progressing and maintenance of patents. It designs and manufactures a range of products, including Auto-retractable Syringe and Manual Retractable Syringe. The Company offers its products for healthcare workers and their patients. Its Blood Collection Device features vacuum technology to capture the needle after blood has been collected. Its Flash Back Needle allows healthcare workers immediate visual confirmation of a venipuncture. The Company's Intravenous Valve operates as a component of the cannula and a standalone device, which is used as access points in the catheters in preference to a syringe for delivering fluid, administering drugs and taking blood samples.

Sector

More about the company